Abstract:Background Although gliomas are confined to the central nervous system, their negative influence over the immune system extends to peripheral circulation. The immune suppression exerted by myeloid cells can affect both response to therapy and disease outcome. We analyzed the expansion of several myeloid parameters in the blood of low- and high-grade gliomas and assessed their relevance as biomarkers of disease and clinical outcome. Methods Peripheral blood was obtained from 134 low- and high-grade glioma patients. CD14 + , CD14 + /p-STAT3 + , CD14 + /PD-L1 + , CD15 + cells and four myeloid-derived suppressor cell (MDSC) subsets, were evaluated by flow cytometry. Arginase-1 (ARG1) quantity and activity was determined in the plasma. Multivariable logistic regression model was used to obtain a diagnostic score to discriminate glioma patients from healthy controls and between each glioma grade. A glioblastoma prognostic model was determined by multiple Cox regression using clinical and myeloid parameters. Results Changes in myeloid parameters associated with immune suppression allowed to define a diagnostic score calculating the risk of being a glioma patient. The same parameters, together with age, permit to calculate the risk score in differentiating each glioma grade. A prognostic model for glioblastoma patients stemmed out from a Cox multiple analysis, highlighting the role of MDSC, p-STAT3, and ARG1 activity together with clinical parameters in predicting patient’s outcome. Conclusions This work emphasizes the role of systemic immune suppression carried out by myeloid cells in gliomas. The identification of biomarkers associated with immune landscape, diagnosis, and outcome of glioblastoma patients lays the ground for their clinical use.

Disease-specific suppressive granulocytes participate in glioma progression

Tumor-specific Neutrophils Originating from Meninges Promote Glioblastoma

Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia.

Myeloid-derived suppressor cells in gliomas

Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas

CSF1R Ligands Expressed by Murine Gliomas Promote M-MDSCs to Suppress CD8+ T Cells in a NOS-Dependent Manner

Myeloid-derived Suppressor Cells and Nonresolving Inflammatory Cells in Glioma Microenvironment: Molecular Mechanisms and Therapeutic Strategies

[Research Progress of Granulocytic Myeloid-derived Suppressor Cells in Non-small Cell Lung Cancer]

Granulocyte-colony stimulating factor promotes proliferation, migration and invasion in glioma cells.

Immune suppression in gliomas

Glioma-derived M-CSF and IL-34 license M-MDSCs to suppress CD8+ T cells in a NOS-dependent manner

The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment

Glioma Stem-Like Cells Evade Interferon Suppression Through MBD3/NuRD Complex-Mediated STAT1 Downregulation

Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma

Oxidative Stress is Involved in Immunosuppression and Macrophage Regulation in Glioblastoma.

Pro-inflammatory and proliferative microglia drive progression of glioblastoma

Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients

Neutrophils: New Critical Regulators of Glioma

Silencing of Forkhead box D1 inhibits proliferation and migration in glioma cells.

Tumor Conditions Induce Bone Marrow Expansion of Granulocytic, but Not Monocytic, Immunosuppressive Leukocytes with Increased CXCR2 Expression in Mice

Neutrophils in glioma microenvironment: from immune function to immunotherapy